TIP Conference: Cogstate’s Mind-Bending Pivot
TIP Conference: Cogstate’s Mind-Bending Pivot
About this video
Cogstate is a neuroscience technology company whose digital cognitive tests are used in clinical trials, historically for Alzheimer’s disease and increasingly for mood disorders such as depression and bipolar. CEO Brad O’Connor says the company signed $25 million in sales contracts in the most recent quarter and already has $56 million of revenue contracted for FY27, plus $40 million for FY28. He explains how that revenue is recognised over the life of each trial, which can run up to eight years for the largest Alzheimer’s studies.
Brad also explains how Cogstate’s mix has changed. In mid-2025 around 80% of contracted future revenue came from Alzheimer’s; that has now fallen to about 40%, with mood, sleep and other neurological conditions making up a similar share. He outlines the company’s five growth drivers, including 78 phase two trials that could move into larger, more valuable phase three contracts from FY28.